Thrombocytopenia: all 703 studies

Page 6 of 8. Open to participants first (151), then studies with results posted, then the rest; newest registration first within each.

• The INFUSE Trial - Intervening With Platelet Transfusions in SepsisWithdrawnNCT03090919Not applicable
• A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant TumorStatus unknownNCT03049774
• Clinical Trial of Gut Microbiota in the Management of Immune ThrombocytopeniaStatus unknownNCT03033199Phase 2
• A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)Status unknownNCT03013114Phase 2
• The PROLONG Trial - Rituximab Maintenance Therapy in ITPCompletedNCT03010202Phase 3
• RP% Measurement by FCM as a Diagnostic Test for ITPStatus unknownNCT02967328
• Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedNCT02948283Phase 1
• Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant WomenStatus unknownNCT02934906
• Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic SyndromesActive, not recruitingNCT02912208Phase 2
• Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous CatheterStatus unknownNCT02906878
• Genotyping of Human Platelet Alloantigens : Non-invasive Prenatal DiagnosisWithdrawnNCT02899598Not applicable
• Immune Thrombocytopenia in PregnancyStatus unknownNCT02892630
• Regulatory B Cells and Chronic Immune ThrombocytopeniaCompletedNCT02891109
• Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT02868099Phase 3
• Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)CompletedNCT02868060Phase 1/2
• Thrombocytopenia Drug Immune Validation of New Biological Test DiagnosticCompletedNCT02862353
• This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)CompletedNCT02859909Phase 3
• Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet TransfusionCompletedNCT02858323
• Efficacy of Sialic Acid GNE Related ThrombocytopeniaCompletedNCT02845609Phase 2
• DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP PatientsStatus unknownNCT02834468Phase 3
• Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT02834286Phase 2
• Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02805868Early Phase 1
• Mathematical Modeling to Predict the Duration of Thrombocytopenia in NeonatesActive, not recruitingNCT02802982
• Rapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill PatientsCompletedNCT02790567
• Pathogen Reduction Evaluation & Predictive Analytical Rating ScoreCompletedNCT02783313Not applicable
• Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) BiomarkersCompletedNCT02780414
• Immunomodulation With Romiplostim in Young Adults With ITPCompletedNCT02760251Phase 4
• Treatment of ITP With Rituximab and / or AccutaneStatus unknownNCT02757196Phase 2
• Thrombocytopenia in Gestational PeriodStatus unknownNCT02751593Phase 2/3
• Vitamin Supplementation in NSCLC Patients on Pemetrexed Based ChemotherapyCompletedNCT02679443Not applicable
• Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune ThrombocytopeniaWithdrawnNCT02649504Phase 3
• Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT02642380Phase 4
• Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune ThrombocytopeniaStatus unknownNCT02627417Phase 3
• Impact of the Platelet Level in Patients Treated for Glioblastoma With TemozolomidCompletedNCT02617745Phase 2
• PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITPTerminatedNCT02566603Phase 1/2
• Caffeic Acid Combining High-dose Dexamethasone in Management of ITPCompletedNCT02556814Phase 4
• Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2CompletedNCT02526485
• Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing HeparinSuspendedNCT02501434Phase 2
• Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLETerminatedNCT02444728Phase 3
• Eltrombopag for Inherited ThrombocytopeniasCompletedNCT02422394Phase 2
• Eltrombopag in Second Line Adult Primary Immune ThrombosytopeniaCompletedNCT02402998Phase 2
• PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITPTerminatedNCT02401061Phase 1/2
• A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in PregnancyCompletedNCT02391272Phase 3
• The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia StudyCompletedNCT02371330
• Caffeic Acid Tablets as a Second-line Therapy for ITPCompletedNCT02351622Phase 3
• The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLCStatus unknownNCT02344979
• An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITPStatus unknownNCT02338414Phase 2
• A Study of Eltrombopag in Patients With CMML and ThrombocytopeniaCompletedNCT02323178Phase 1/2
• Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALLCompletedNCT02314273Phase 4
• Bleeding Prediction in ThrombocytopeniaCompletedNCT02306044
• Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune ThrombocytopeniaCompletedNCT02298075
• Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)CompletedNCT02287649Not applicable
• Observational Trial of a Therapeutic Platelet Transfusion RegimenTerminatedNCT02276651
• Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in PregnancyStatus unknownNCT02270801Phase 3
• Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsCompletedNCT02267993Phase 4
• Evaluate the Association Between Infection and ThrombocytopeniaCompletedNCT02263157
• Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic LeukemiaStatus unknownNCT02244658Phase 3
• Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of ThrombocytopeniaStatus unknownNCT02241031Phase 2/3
• Prevention of Thrombocytopenia in Glioblastoma PatientsTerminatedNCT02227576Phase 2
• A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02203422Phase 3
• An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)CompletedNCT02153060Phase 2
• An Investigation of rhTPO With Different Frequencies in the Management of ITPCompletedNCT02139501Phase 3
• A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）WithdrawnNCT02137681Phase 3
• rhTPO in Critical Patients With ThrombocytopeniaStatus unknownNCT02094248Phase 2/3
• A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced ThrombocytopeniaStatus unknownNCT02093325Phase 3
• Blood Products in Cardiac SurgeryCompletedNCT02068755
• An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune ThrombocytopeniaCompletedNCT02063789Phase 3
• TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.CompletedNCT02063763
• Occupational Status and Hematological DiseaseCompletedNCT02057185
• A Chart Review of Rituximab Plus Repeated Cycles of DexamethasoneTerminatedNCT02050581
• Study of Immune Thrombocytopenia Pathogenesis:CompletedNCT02042560
• A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White SubjectsCompletedNCT02039076Phase 1
• Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe ThrombocytopeniaTerminatedNCT02032134Phase 4
• Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B CirrhosisStatus unknownNCT01987791
• Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem CellCompletedNCT01980030Phase 1/2
• High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITPWithdrawnNCT01976195Phase 2
• Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood DyscrasiaCompletedNCT01974401Phase 2
• A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013CompletedNCT01974232
• ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITPCompletedNCT01971684
• The International ITP RegistryStatus unknownNCT01970189
• A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITPCompletedNCT01965626Phase 2
• Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.CompletedNCT01933035
• Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With ThrombocytopeniaCompletedNCT01928017
• All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01882127Phase 3
• The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune ThrombocytopeniaWithdrawnNCT01869049
• Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag TreatmentWithdrawnNCT01864512
• A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia PurpuraCompletedNCT01808521Early Phase 1
• Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITPStatus unknownNCT01805648Phase 3
• Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.CompletedNCT01791101Phase 2
• Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction ProcessCompletedNCT01789762Phase 4
• Oxidant Status and Effect of Antioxidant in Immune ThrombocytopeniaStatus unknownNCT01763658Phase 2/3
• Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)WithdrawnNCT01734057Phase 3
• Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin MimeticsCompletedNCT01727999
• Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With ThrombocytopeniaTerminatedNCT01727401Phase 4
• Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune ThrombocytopeniaCompletedNCT01727232
• Efficacy of Rapamycin Therapy With Chronic Immune ThrombocytopeniaCompletedNCT01672151
• Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune ThrombocytopeniaCompletedNCT01668615
• The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune ThrombocytopeniaCompletedNCT01667263Phase 2
• Autoantibody Specificity and Response to IVIG in ITPCompletedNCT01666795
• A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11CompletedNCT01663441Phase 3

← Thrombocytopenia overview